KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Equity Income (2019 - 2022)

Biogen has reported Equity Income over the past 8 years, most recently at $3.4 million for Q3 2022.

  • Quarterly results put Equity Income at $3.4 million for Q3 2022, down 92.44% from a year ago — trailing twelve months through Jun 2023 was $3.4 million (down 97.42% YoY), and the annual figure for FY2022 was $2.6 million, down 92.55%.
  • Equity Income for Q3 2022 was $3.4 million at Biogen, down from $45.0 million in the prior quarter.
  • Over the last five years, Equity Income for BIIB hit a ceiling of $45.0 million in Q2 2021 and a floor of -$28.7 million in Q1 2019.
  • Median Equity Income over the past 4 years was $25.9 million (2019), compared with a mean of $15.7 million.
  • Biggest five-year swings in Equity Income: surged 307.36% in 2020 and later plummeted 92.44% in 2022.
  • Biogen's Equity Income stood at $33.8 million in 2019, then plummeted by 46.75% to $18.0 million in 2020, then surged by 150.0% to $45.0 million in 2021, then plummeted by 92.44% to $3.4 million in 2022.
  • The last three reported values for Equity Income were $3.4 million (Q3 2022), $45.0 million (Q2 2022), and -$3.3 million (Q1 2022) per Business Quant data.